Breaking News

Putin, Poroshenko Agree on Cease-Fire in Ukraine
Tweet TWEET

Savient Pharmaceuticals Announces the Election of Genzyme CEO Dr. David Meeker to Its Board of Directors

Savient Pharmaceuticals Announces the Election of Genzyme CEO Dr. David Meeker
                          to Its Board of Directors

PR Newswire

BRIDGEWATER, N.J., Jan. 8, 2013

BRIDGEWATER, N.J., Jan. 8, 2013 /PRNewswire/ --Savient Pharmaceuticals, Inc.
(NASDAQ: SVNT) announced today that David Meeker, M.D., President and Chief
Executive Officer of Genzyme, a Sanofi Company, has been elected to Savient's
Board of Directors, effective January 7, 2013. In addition, Savient announced
the resignation from the Company's Board of William F. Owen, Jr., M.D., who is
relocating to Qatar to serve as Chief Executive Officer of the Sidra Medical
and Research Center, a groundbreaking medical, research and education
institution that focuses on the health and wellbeing of women and children in
Doha, Qatar. With the election of Dr. Meeker and the departure of Dr. Owen,
the number of Savient Board members remains seven.

"David's extensive knowledge of the life sciences industry and his expertise
in developing therapeutic products and leading a renowned team at Genzyme will
be great assets to Savient, and we look forward to his contributions to our
Board," stated Stephen O. Jaeger, Chairman of Savient's Board of Directors.
"We also are grateful to Dr. Owen for his many contributions and his role in
the progress of Savient."

Dr. Meeker was appointed President and Chief Executive Officer of Genzyme, a
Sanofi Company, in October 2011. Prior to this, he held key positions of
increasing responsibility at Genzyme, first within Research and Development
and then within the commercial organization.Most recently he servedas Chief
Operating Officer, in which capacity he was responsible for Genzyme's
commercial organization and played an important role in the company's
integration with Sanofi. Previous positions at Genzyme included President of
the Global Rare Disease Business, in which role Dr. Meeker oversaw the global
launches of Aldurazyme^®, Fabrazyme^®, and Myozyme^®. Prior to joining
Genzyme, Dr. Meeker served as the Director of the Pulmonary Critical Care
Fellowship at the Cleveland Clinic and as an assistant professor of medicine
at Ohio State University. He currently is a Board member of the Biotechnology
Industry Organization and of Prize4Life. Dr. Meeker received his M.D. degree
from the University of Vermont Medical School and completed the Advanced
Management Program at Harvard Business School.

"David brings a unique history in the industry, having overseen important
global product launches in rare diseases, as well as gaining insights into the
patient perspective by serving in one of the leading teaching hospitals in the
U.S.," said Lou Ferrari, President and Chief Executive Officer of Savient. "I
believe David's vision and his track record will be extremely important for
Savient as we continue to offer an important treatment option for patients
suffering from refractory chronic gout and as we prepare for the anticipated
approval and launch of KRYSTEXXA® in the EU."

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused
on developing and commercializing KRYSTEXXA^® (pegloticase) for the treatment
of chronic gout in adult patients who do not respond to conventional therapy.
Savient has exclusively licensed worldwide rights to the technology related to
KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View
Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme
and MVP developed the PEGylation technology used in the manufacture of
KRYSTEXXA. MVP and Duke have been granted US and foreign patents disclosing
and claiming the licensed technology and, in addition, Savient owns or co-owns
US and foreign patents and patent applications, which collectively form a
broad portfolio of patents covering the composition, manufacture and methods
of use and administration of KRYSTEXXA. Savient also supplies Oxandrin^®
(oxandrolone tablets, USP) CIII in the US For more information, please visit
the Company's website at www.savient.com.

Contact:
Savient Pharmaceuticals, Inc.                     Burns McClellan
John P. Hamill                                    Caitlyn Murphy
Senior Vice President and Chief Financial Officer cmurphy@burnsmc.com
information@savient.com                           (212) 213-0006
(732) 418-9300

SVNT - G

SOURCE Savient Pharmaceuticals, Inc.

Website: http://www.savient.com
 
Press spacebar to pause and continue. Press esc to stop.